Development of a universal assay for minimal residual disease in acute myeloid leukemia using duplex sequencing

Ended Grant Awarded Last action

Award ID
R44CA233381
Recipient
Awarding agency
Obligated
$5,005,321

Award facts

Assistance listing
93.394 Cancer Detection and Diagnosis Research
Completion date
Originally
Place of performance
Seattle, WA 98121, USA

Award details come from USAspending.gov.

Transactions

Action Obligated Date
Amendment -$659,483
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $1,985,831
Amendment $0
Amendment $0
Amendment $1,139,103
Amendment $0
Amendment $249,982
Amendment $30,486
Amendment $579,262
Amendment $690,175
Amendment $0
Amendment $0
Amendment $690,175
Original award $299,790
Show all 18

Quick answers

Who received award R44CA233381?

R44CA233381 was awarded to Twinstrand Biosciences Inc. by National Cancer Institute (National Institutes of Health) on July 16, 2018.

How much is award R44CA233381 worth?

$5,005,321 has been obligated on R44CA233381.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award